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TO THE EDITOR
Pseudoxanthoma elasticum (PXE;
OMIM#264800) is characterized by
progressive, late-onset, ectopic minera-
lization of elastic fibers, clinically affect-
ing skin, retina, and the cardiovascular
system with considerable morbidity and
occasional mortality (Neldner, 1988). It
is an autosomal recessive disorder with
a slight female preponderance and an
estimated prevalence of B1 in 50,000–
70,000. The clinical diagnosis is usually
made through recognition of characteri-
stic skin lesions, i.e., small, yellowish
papules on flexural areas progressively
coalescing into plaques of inelastic,
leathery skin. The cutaneous findings
are associated with angioid streaks in
the retina and mineralization of arterial
blood vessels. Adding to the diagnostic
difficulty is the considerable phenotypic
heterogeneity in age at onset and the
extent and severity of organ system
involvement. Since the identification of
mutations in the ATP-binding cassette,
subfamily C, member 6 gene (ABCC6)
as the genetic basis in the overwhelming
majority of families with PXE, tremen-
dous progress has been made in
understanding the molecular genetics,
clinical phenotypes, and pathogenesis
of this disease (Uitto et al., 2010).
Mutations in the ABCC6 gene under-
lie the classic form of PXE, and over 300
distinct mutations representing over
1,000 mutant alleles have been reported
(Uitto et al., 2010). However, no
apparent correlation has been establi-
shed between PXE phenotypes and the
nature or the position of the mutations
in ABCC6 (Pfendner et al., 2007).
Genetic variations in gamma-glutamyl
carboxylase (GGCX) (Vanakker et al.,
2007; Li et al., 2009), secreted phospho-
protein 1 (SPP1) (Hendig et al., 2007),
and xylosyltransferase I (XYLT) (Schon
et al., 2006) genes, together with
environmental risk factors such as diet
(LaRusso et al., 2009), appear to modify
the phenotype with respect to the age at
onset and the extent and severity of
organ involvement in PXE.
Understanding of the mechanisms
underlying PXE has been advanced by
the development of targeted mutant
mice with genetic, histopathological,
and ultrastructural features similar to
those in patients with PXE (Gorgels
et al., 2005; Klement et al., 2005). A
characteristic finding in the targeted
mutant mouse (B6;129S1/SvImJ-
Abcc6tm1Jfk) is the mineralization of the
vibrissae dermal sheaths, the principal
components of which were calcium and
phosphorus (Kavukcuoglu et al., 2012).
This specialized hair follicle type is not
found in humans, and mineralization
of the vibrissae dermal sheath is very
unusual in mice. The genetic back-
ground of mice can modify phenotypes
associated with a single gene mutation
as is the case with this Abcc6tm1Jfk-null
Abbreviations: ATP-binding cassette, subfamily C, member 6 (gene symbol: Abcc6, mice; ABCC6, human;
protein symbol for both: ABCC6); secreted phosphoprotein 1 (gene symbol: SPP1, human); SUMO/sentrin-
specific peptidase 6 (gene symbol: SENP6, human; Senp6, mouse); xylosyltransferase I (gene symbol:
XYLT, human; Xylt1 and 2, mouse); Casr, calcium-sensing receptor; DCC, dystrophic cardiac calcinosis;
PXE, pseudoxanthoma elasticum; SNP, single-nucleotide polymorphism
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mouse (Li and Uitto, 2010). Dystrophic
cardiac calcinosis (DCC) in C3H/HeJ
mice is also associated with a polymor-
phism in the Abcc6 gene (Aherrahrou
et al., 2008), but these mice lack
vibrissa mineralization (Figure 1). These
observations suggested that spontaneous
mutations in Abcc6 may exist in inbred
mouse strains and such mice would
then provide novel models to study
detailed mechanisms of PXE, especially
for defining the role of modifier genes.
In a large-scale aging study of 31
inbred strains (Supplementary Table S1
online), mineralization of vibrissae der-
mal sheaths was routinely diagnosed
histologically in KK/HlJ mice 6 months
of age and older and in very old 129S1/
SvImJ mice (Figure 1, Table 1, Supple-
mentary Table S1 online). One case out
of 68 RIIIS/J mice examined had vibris-
sae mineralization at the age of 20
months. Mineralization of various inter-
nal organs was observed with distinct
strain distributions (Supplementary Table
S2 online). Vibrissae mineralization and
other PXE-like lesions (mineralization of
medium-sized arteries, retina, lung, and
dermis) were particularly severe in the
KK/HlJ strain. KK/HlJ mice also had a
number of other pathological findings,
including severe fibro-osseous lesions of
bones (Figure 1), as well as epicardial
mineralization and fibrosis (i.e., DCC)
(Table 1). The fibro-osseous bone lesion
was found in a number of strains without
PXE-like mineralization and was not
associated with mineralization of elastic
fibers, indicating that it most likely
represents an unrelated disease, or that
Abcc6 was a strong modifier gene in KK/
HIJ mice when mutated (Berndt and
Sundberg manuscript in preparation).
Haplotype analysis of Abcc6 revealed
that one nonsynonymous single-nucleo-
tide polymorphism (SNP) was associated
with tissue mineralization. Specifically,
the SNP in exon 14 (rs32756904)
showed an A allele at base pair position
53,257,951 on chromosome 7 in KK/HlJ
and 129S1/SvImJ—strains with vibrissae
mineralization—but a G allele in strains
without those lesions (Table 1). The
phenotypic differences between the
strain groups with the various alleles
were significant (Supplementary Table
S2 online). The only exception was one
out of 68 RIIIS/J mice, which had vibris-
sae mineralization. RIIIS/J mice have a G
allele at rs32756904 in exon 14. The
SNP was confirmed by sequencing in
all strains shown in Table 1. This SNP
was recently shown in KK/HlJ mice to
create a novel splice donor site, which
results in the deletion of five nucleotides
at the end of exon 14, causing a frame-
shift of the reading frame and a pre-
mature termination codon of translation
(Li et al., 2012), similar to previous
findings in C3H/HeJ mice (Aherrahrou
et al., 2008).
Examination of modifier genes for
human PXE, including GGCX (Vanakker
et al., 2007) (i.e., Ggcx), SSP1 (i.e.,
Senp6), and XYLT (i.e., Xylt1 and Xylt2),
as well as the calcium-sensing receptor
(Casr) in mice (Hough et al., 2004), did
not reveal differential SNP patterns
a c d e f g hb
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Figure 1. Vibrissae mineralization and fibro-osseous bone lesions. Sections of vibrissae from a 375-day-old female C3H/HeJ mouse have no mineralization
of the connective connective tissue sheath (a–f) as demonstrated by hematoxylin and eosin staining (a, b, i, g), whereas those from a KK/HlJ mouse are mineralized
(i–n), confirmed by von Kossa (c, d, k, l) and alizarin red (e, f, m, n) stains. Normal cortical bone and bone marrow from a female C3H/HeJ mouse
(g, h) is very different from that of a 555-day-old female KK/HlJ mouse (o, p) with fibro-osseous lesions. Note the thin cortex and effacement of the bone
marrow by fibrovascular stroma in the KK/HlJ mouse (aldehyde fuchsin stain).
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between affected and unaffected strains.
DCC, characterized by mineralization
and fibrosis of the heart, has been
shown to be associated with four quanti-
tative trait loci (Dyscalc1-4) from a cross
between C3H/HeJ and C57BL/6J mice
(Meng et al., 2007). Dyscalc1 is now
listed as Abcc6 (http://www.informatics.
jax.org). Combined with observations
that similar lesions occur in strains
without the vibrissae mineralization
(Table 1, Supplementary Table S2
online) and that relatively few heart
lesions occur in the Abcc6tm1Jfk-null mice
(Klement et al., 2005), it is likely that the
cardiac lesions may not be primarily
associated with Abcc6 mutations but
that Abcc6 may rather be a major modi-
fier of DCC phenotypes.
KK/HlJ, and to a lesser extent 129S1/
SvImJ, mice provide potential new spon-
taneous models that may be useful for
studying PXE-like phenotypes (Li et al.,
2012). Other lesions in these mice with
various degrees of mineralization may
be part of the overall pathologic
process: they may reflect the expres-
sion of the influence of strain-specific
modifier genes, or may represent new
clinical variations.
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TO THE EDITOR
Psoriasis is a chronic immune-mediated
and hyperproliferative disorder of the
skin that affects 2–3% of the population.
Psoriasis is associated with an increased
incidence of several cardiovascular and
metabolic comorbidities, including cor-
onary artery disease (CAD), hyper-
tension, obesity, hyperlipidemia, and
type 2 diabetes (T2D) (Davidovici
et al., 2010). The association of these
cardiovascular and metabolic diseases
with psoriasis could be due to shared
genetic risk variants, shared environ-
mental triggers, activation of common
inflammatory pathways, or a combina-
tion of these factors. Here, we evaluated
the hypothesis that some of the increa-
sed risk for cardiovascular and meta-
bolic diseases in psoriasis is derived
from shared genetic risk factors.
Using the genome-wide association
studies (GWAS) catalog (available at
www.genome.gov/gwastudies and acc-
essed in December 2011), we selected
363 single-nucleotide polymorphisms
(SNPs) that showed significant associa-
tion with CAD, hypertension, body mass
index (BMI), hyperlipidemia (total, low-
density lipoprotein (LDL), and high-den-
sity lipoprotein (HDL) cholesterol levels
and triglyceride levels), or T2D. Selected
SNPs met genome-wide significance
(Po5108) in at least two GWAS or
were significant in the latest meta-ana-
lysis of GWAS. Additional SNPs or loci
were also included on the basis of latest
expert opinions (McCarthy, 2010;
O’Donnell and Nabel, 2011; Peden
and Farrall, 2011). Detailed information
about the selected SNPs is provided in
Supplementary Table S1 online.
We evaluated the selected cardio-
vascular and metabolic SNPs for asso-
ciation with psoriasis in four psoriasis
GWAS cohorts: the GAIN cohort includ-
ing 1,368 psoriasis cases and 1,348
controls (Nair et al., 2009), an
unpublished psoriasis cohort from
Sweden including 725 cases and 438
controls, a Washington University/
University of California San Francisco
cohort including 211 psoriasis cases and
502 controls (Liu et al., 2008), and the
Wellcome Trust Case–Control Consor-
tium cohort including 2,178 psoriasis
cases and 5,175 controls (Strange et al.,
2010). Further details of the Swedish
cohort are described in the Supple-
mentary Methods online. IMPUTE2 was
used to impute the ungenotyped SNPs
using phase 3 HapMap and 1,000 Gen-
omes pilot project CEU haplotypes as a
reference. SNPTEST was used to associ-
ate the imputed dosage for each SNP
with psoriasis status separately in each
study population with adjustment of
the first three principal components
from a multidimensional scaling
analysis of population stratification.
The association test results for these
SNPs with relatively high confidence
(PROPER_Info40.5) were then com-
bined by meta-analysis with the META
using the inverse-variance method based
on a fixed-effect model. The false dis-
covery rate method was used to correct
for multiple testing (FDR_qo0.05).
We first examined the associations
between all selected SNPs and psoriasis
status (Table 1 and Supplementary
Table S2 online). After adjusting for
multiple testing with the false discovery
rate method, seven SNPs were found
to be associated with psoriasis status
(FDR_qo0.05, Table 1). The alleles
associated with increased risk for
dyslipidemia (rs2247056, rs3177928,
rs492602, and rs181362), increased
blood pressure levels (rs805303,
rs653178, and rs3184504), and increa-
sed risk for CAD (rs3184504) were ass-
ociated with increased risk for psoriasis
(Table 1). The top three SNPs
(rs2247056, rs3177928, and rs805303)
were located in the HLA gene region,
which is a known psoriasis susceptibility
locus. After further adjustment for the
top psoriasis risk allele HLA-C*06:02
(determined by imputation as described
in Chen et al., 2012), the associa-
tions for rs2247056 and rs3177928
were mitigated (P¼ 0.06 and 0.07,
respectively), whereas the association
for rs805303 persisted (P¼ 0.005). As
multiple psoriasis risk alleles are
Abbreviations: BMI, body mass index; CAD, coronary artery disease; GWAS, genome-wide association
studies; HDL, high-density lipoprotein; LD, linkage disequilibrium; LDL, low-density lipoprotein; SNP,
single-nucleotide polymorphism; T2D, type 2 diabetes; wGRS, weighted gene risk score
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